Clinical Trials in the USA / NCT02151175
Enrolling by invitation
Not applicable
Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy
NCT02151175 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Epilepsy, Temporal Lobe
Investigational drug(s) / intervention(s)
LIFUP
Study summary
We intend to use focused ultrasound to stimulate or suppress brain activity in patients with epilepsy. We hypothesize that focused ultrasound is capable of brain stimulation or suppression visible with functional MRI, and will not cause tissue damage.
Eligibility
Inclusion Criteria:
* Subjects with clinical evidence from their diagnostic evaluations of unilateral hippocampal dysfunction and epileptogenicity.
* Subjects with seizures that have been refractory to treatment with at least three currently marketed antiepileptic drugs.
* Subjects with epilepsy who would clearly benefit from surgical intervention.
* Subjects who have been offered a non-dominant anterior-mesial temporal lobe resection as treatment for medication refractory epilepsy.
Exclusion Criteria:
* Subjects with a cognitive or psychiatric disorder that limits the ability to give informed consent or are unable to cooperate with the testing.
* Subjects with dementia, delirium and psychotic symptoms. - Subjects with ferromagnetic materials in the head.
* Subjects with severe cardiac disease, increased intracranial pressure, or a TENS unit.
* Subjects who exhibit primary generalized seizures or pseudoseizures.
* Subjects who have seizures secondary to drugs, alcohol, metabolic illness or progressive degenerative disease.
* Subjects who have experienced status epilepticus during the 3-week baseline period prior to the operation.
* Subjects (females) who are pregnant.
Primary outcome measure(s)
- Absence of histological changes — 7 days
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| UCLA | Los Angeles | California |
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT02151175 on ClinicalTrials.gov ↗ ← All trials in the USA